The landscape of lung cancer treatment has undergone a significant transformation with the advent of immunotherapy, offering renewed hope and…
Read More
Novo Nordisk’s triple agonist UBT251 delivered up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, has announced promising results from a Phase 2 trial of…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry grapples with an intractable challenge: the escalating cost and protracted timelines of drug development, coupled with persistently…
Read More
From list price to net price: How finance leaders decode real drug costs
In the intricate landscape of the healthcare industry, discussions surrounding drug pricing often commence and conclude with the enigmatic "list…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial.
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Lilly Ascends to Top Pharma Company by Revenue in FY2025, Fueled by Mounjaro and Zepbound’s Explosive Growth
Eli Lilly and Company has officially claimed the top position in the global pharmaceutical industry by revenue for fiscal year…
Read More
MEDVi: The AI-Powered Telehealth Startup Under Fire Amidst FDA Warnings, Deception Allegations, and Mounting Lawsuits
In an era increasingly shaped by artificial intelligence, the promise of rapidly scalable, AI-driven enterprises has captivated the global imagination.…
Read More
Pharma 50: Keytruda Holds Top Brand Slot as Tirzepatide and Semaglutide Dominate at Molecule Level in FY2025
The pharmaceutical industry’s financial landscape underwent a significant transformation in fiscal year 2025, revealing a nuanced shift in leadership despite…
Read More
Pharma 50: The 50 best-selling drugs of FY2025
The pharmaceutical landscape in Fiscal Year 2025 was defined by a monumental shift at the very apex of the industry’s…
Read More
FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine
The U.S. Food and Drug Administration (FDA) has officially reversed its earlier decision regarding Moderna’s investigational mRNA influenza vaccine (mRNA-1010),…
Read MoreYOU MAY HAVE MISSED
